Skip to main content
Download PDF

Blocking P2X7 by intracerebroventricular injection of P2X7-specific nanobodies reduces stroke lesions

Journal of Neuroinflammation volume 19, Article number: 256 (2022) Cite this article

This article has been updated

Abstract

Background

Previous studies have demonstrated that purinergic receptors could be therapeutic targets to modulate the inflammatory response in multiple models of brain diseases. However, tools for the selective and efficient targeting of these receptors are lacking. The development of new P2X7-specific nanobodies (nbs) has enabled us to effectively block the P2X7 channel.

Methods

Temporary middle cerebral artery occlusion (tMCAO) in wild-type (wt) and P2X7 transgenic (tg) mice was used to model ischemic stroke. Adenosine triphosphate (ATP) release was assessed in transgenic ATP sensor mice. Stroke size was measured after P2X7-specific nbs were injected intravenously (iv) and intracerebroventricularly (icv) directly before tMCAO surgery. In vitro cultured microglia were used to investigate calcium influx, pore formation via 4,6-diamidino-2-phenylindole (DAPI) uptake, caspase 1 activation and interleukin (IL)-1β release after incubation with the P2X7-specific nbs.

Results

Transgenic ATP sensor mice showed an increase in ATP release in the ischemic hemisphere compared to the contralateral hemisphere or the sham-treated mice up to 24 h after stroke. P2X7-overexpressing mice had a significantly greater stroke size 24 h after tMCAO surgery. In vitro experiments with primary microglial cells demonstrated that P2X7-specific nbs could inhibit ATP-triggered calcium influx and the formation of membrane pores, as measured by Fluo4 fluorescence or DAPI uptake. In microglia, we found lower caspase 1 activity and subsequently lower IL-1β release after P2X7-specific nb treatment. The intravenous injection of P2X7-specific nbs compared to isotype controls before tMCAO surgery did not result in a smaller stroke size. As demonstrated by fluorescence-activated cell sorting (FACS), after stroke, iv injected nbs bound to brain-infiltrated macrophages but not to brain resident microglia, indicating insufficient crossing of the blood–brain barrier of the nbs. Therefore, we directly icv injected the P2X7-specific nbs or the isotype nbs. After icv injection of 30 µg of P2X7 specific nbs, P2X7 specific nbs bound sufficiently to microglia and reduced stroke size.

Conclusion

Mechanistically, we can show that there is a substantial increase of ATP locally after stroke and that blockage of the ATP receptor P2X7 by icv injected P2X7-specific nbs can reduce ischemic tissue damage.

Introduction

Stroke induces sterile inflammation, which worsens the initial brain damage and neurological outcome [1, 2]. Hypoxic brain tissue releases many molecules, which can activate cells such as microglia in the surrounding tissue and lead to infiltration of other immune cells such as neutrophils, amplifying the inflammatory cascade [3]. These molecules include adenosine triphosphate (ATP) as well as nicotinamide adenine dinucleotide (NAD), heat shock protein (HSP), and high-mobility group box 1 protein (HMGB1). These factors can activate the inflammasome and induce the secretion of proinflammatory cytokines by innate immune cells [4, 5]. These molecules activate several pathways, such as the ATP/P2X7 pathway or the nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) pathway [6]. The P2X7 receptor is a homotrimeric, ligand-gated nonselective cation channel that is expressed in the central nervous system as well as on immune cells [7]. The P2X7 receptor consists of three polypeptide subunits, each with two transmembrane domains [8, 9]. After activation by extracellular ATP (eATP), these subunits form an ion-permeable channel, which induces Na+ and Ca2+ influx and K+ efflux, resulting in plasma membrane depolarization and initiation of Ca2+ signaling cascades. The K+ efflux through the P2X7 receptor supports the formation of the Nod-like receptor protein 3 (NLRP3)-mediated inflammasome complex, which cleaves pro-caspase 1 and leads to a subsequent cleavage of pro-IL-1β and pro-IL-18 into their biologically active forms [5, 10, 11]. The amount of accessible intracellular pro-IL-1β and pro-IL-18 also depends on another signal transmitted by receptors, such as Toll-like receptors (TLRs) or tumor necrosis factor (TNF)-receptors, and subsequent NFκB activation.

In the central nervous system (CNS), P2X7 has been found primarily on microglia, with less on astrocytes and oligodendrocytes [12,13,14,15,16,17]. These findings were confirmed by data from the Allen Brain Atlas for mice [18] and humans [19]. There are some similarities between human and rodent P2X7 expression in the brain, such as high expression on microglia and low expression on astrocytes, but there are also some differences such as high expression of P2X7 on human oligodendrocytes and low expression on rodent oligodendrocytes.

Several studies have shown that the experimental stroke size in P2X7−/− mice is smaller than that in wild-type mice [20, 21]. In addition, blocking the P2X7 channel with brilliant blue G (BBG) attenuated ischemic damage [20]. However, systemic BBG cannot be used in humans since it is nonspecific and toxic.

Nanobodies (nbs), named for their small size (2.5 nm diameter, 4 nm height, 12 kDa) [22], are single-domain antibodies derived from camelid heavy chain antibodies. Compared to small molecule inhibitors, nbs have key advantages, such as low toxicity, high specificity, no off-target effects and, in the case of P2X7, a more potent inhibition [10, 21, 23]. With their long complementarity determining region 3 (CDR3), these molecules can access cavities or clefts on membrane proteins that are often inaccessible to antibodies [24, 25]. Other advantages of nbs over conventional antibodies include high stability, better solubility and rapid and targetable in vivo biodistribution. In addition, the ability to form nb multimers and the low costs and ease of production make them ideal candidates for treatment [26]. Fusion of an nb (monomer or multimer) to the Fc domain of a conventional antibody yields a heavy chain antibody with reconstituted Fc-mediated effector functions, including binding to Fc receptors, extended half-life and complement activation. This phenomenon allows a much broader tailoring of nbs than of conventional antibodies to different pathophysiologies [27].

In this proof-of-concept study, we used P2X7-specific nbs to treat mice directly before temporary middle cerebral artery occlusion (tMCAO) surgery. We found that these nbs need to be injected intracerebroventricularly to reach P2X7 receptor on brain resident cells and protect against ischemic stroke.

Methods

Animals

All animal experiments were approved by the local animal care committees (Behörde für Justiz und Veterinärwesen Hamburg, Nr 006/18) and conducted following the “Guide of the Care and Use of Laboratory Animals” published by the US National Institutes of Health (NIH Publication No. 83–123, revised 1996). All mice were kept at a constant temperature of 22 ± 2 °C with a 12-h light–dark cycle and ad libitum access to food and water. Only 12- to 18-week-old male mice were used for this study. C57BL/6J mice were purchased from Charles River (Bar Harbor, ME 04609, USA), whereas the generation of pmeLUC transgenic and P2X7-EGFP transgenic mice (line 17 in C57BL/6J) was described previously [28, 29].

Production of P2X7 nbs

The P2X7-antagonizing nbs 1c81 and 13A7 were selected and cloned into the pCSE2.5 expression vector (kindly provided by Thomas Schirrmann, Braunschweig, Germany) [30] as described previously [10, 28]. Then, 13A7 was fused to the hinge, constant domain heavy chain (CH) 2, and CH3 domains of mouse immunoglobulin (Ig) G2c, resulting in a heavy chain format (nb A), whereas 1c81 was dimerized and fused to the albumin-specific nb Alb8 (mAb77) [31], resulting in a bispecific heterotrimeric nb with an extended half-life (nb B) (Additional file 1: Fig. S1). Since dimers showed a higher potency than monomers [10], we used nb B for intracerebroventricular (icv) injection. For icv injection, we needed to create a construct that could be highly concentrated without aggregation, so we modified our nb B (Additional file 1: Fig. S1). The modified nb B-mod was concentrated up to 15 μg/μl without aggregation. The exact sequences and further information on the various constructs can be found in patent WO/2013/178783.

HEK-6E cells were transfected with the constructs, and 6 days after transfection, the nbs were purified from the cell supernatant by affinity chromatography on a protein-G Sepharose column. The buffer was exchanged by gel filtration on a PD-10 column. The concentration and purity were monitored by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and a BCA™ Protein Assay Kit (Pierce).

tMCAO surgery and stroke size analysis

tMCAO was performed as previously described [32,33,34]. Mice were anesthetized with 1.5% isoflurane in 100% O2 and an intraperitoneal injection of 0.05 mg/kg body weight buprenorphine in saline was used as analgesic. A midline skin incision in the neck was made before ligating the proximal common carotid artery (CCA) and the external carotid artery (ECA) without disrupting the venous vessels. Vital parameters were continuously monitored with PhysioSuite (Kent Scientific Corporation, USA). Occlusion was confirmed by a laser Doppler monitor (moorVMS-LDF; Moor Instruments, UK) and persisted for 40 min. Mice with an occlusion rate of less than 80% were excluded.

Stroke size was measured by triphenyl tetrazolium chloride (TTC) staining and magnetic resonance imaging (MRI). We used a 7-Tesla MR small animal imaging system (ClinScan, Bruker, Ettlingen, Germany). The imaging protocol comprised T2-weighted imaging MRI. Calculation of corrected stroke volumes was performed as described previously [35].

The infarct volumes and total areas of the treated hemisphere were calculated using NIH ImageJ software.

Intravenous (iv) and icv injections of nbs

Different methods of nb administration were used. P2X7-specific nbs (nb A, 13A7-Fc) were directly injected (100 µg in 100 µl of phosphate-buffered saline [PBS]) intravenously, or P2X7-specific nbs (nb B/nb B-mod, 1c81-dim-HLE) or isotype nbs against human cluster-of-differentiation (CD) 38 were injected (30 µg in 2 µl of PBS containing 60 mg/ml trehalose and 0.4 mg/ml Tween-20) directly into the ventricles of the brain by using a stereotaxic apparatus. Mice were pain treated with 1 mg tramadol/kg body weight one day before surgery. Directly before the surgery, the mice were anesthetized with isoflurane (4% for induction, 2.5% for maintenance) in 100% oxygen. After placing the mice in a stereotactic frame (Stoelting, 51615), we made a 1-cm-long incision above the midline. A cranial burr hole (0.9 mm) was drilled 1.1 mm lateral and 0.5 mm posterior to the bregma. Nbs were drawn into a 10-μl Hamilton syringe (Hamilton, 1701RN) connected to a 26-gauge needle (Hamilton, 26G, Point Style 4, 12°) controlled by a motorized stereotaxic injector (Stoelting, integrated stereotaxic injector [ISI]).

The needle was slowly introduced 2.3 mm deep into the left ventricle (Additional file 1: Fig. S2). Following a period of 5 min to let the ventricular system re-expand, 2 μl of dissolved nbs at a concentration of 15 μg/μl was injected at 1 μl/min. This step was followed by another 10-min break and slow removal of the needle. Vital parameters were monitored by an animal support unit (Minerve, Esternay, France). Body temperature was maintained throughout the procedure at 37 °C using a feedback-controlled heating device.

In vivo ATP measurement after tMCAO using pmeLUC-TG

Three hours before tMCAO surgery, 150 mg/kg luciferin (Promega) was injected intraperitoneally. Luciferin was reinjected 1 day after tMCAO in prior of the measurement. In vivo ATP release was monitored by whole-body luminometry performed using the IVIS-Perkin Elmer in vivo imaging system. In vitro calibration was performed in brain homogenates from pmeLUC-tg mice.

Microglia and macrophage preparation and FACS

Animals were euthanized and perfused with PBS. Brains were dissected and digested in 1 mg/ml collagenase A (Roche) and 0.1 mg/ml DNase type I (Sigma). Separation from myelin and debris was performed by density centrifugation with Percoll (GE Healthcare). The following antibodies and detection systems were used: CD45-APC-Cy7 (1:100, 30-F11, #103,115 BioLegend), CD45-PerCP (1:100, 30-F11, #103,129, BioLegend), CD11b-APC (1:100, M1/70, #17–0112-82, eBioscience), Ly6C-PerCP/Cy5.5 (1:100, HK1.4, #128,011, BioLegend), anti-mIgG1-brilliant violet (BV) 421 (1:100, RMG1-1, #406,615, BioLegend), anti-mIgG2-BV421 (1:100, RM223, #31–1103-02, Dianova), steptavidin-BV421 (1:100, #405,226, BioLegend), Fc blocking anti-CD16/CD32 (1:100, 2.4G2, #BE0307, BioXcell), and mAb77 (1:100, Alb8-specific mouse monoclonal antibody kindly provided by Ablynx). Microglia were gated as mentioned in the supplementary materials (Additional file 1: Fig. S3). In the first step, cells were incubated (30 min on ice) with Fc blocking anti-CD16/32, where ex vivo samples were incubated with 0.5 μg of P2X7 specific nb in the presence of Fc blocking anti-CD16/32. For detection of cell-bound P2X7 nbs, cells were incubated either with biotinylated anti-mouse IgG2c-fused antibody followed by streptavidin BV421 conjugated (nb A) or with mAb77 (nb B-mod) followed by fluorochrome-conjugated antibodies in the presence of Fc blocking anti-CD16/CD32 (Additional file 1: Fig. S1). Calcium influx was measured by a Fam-fluorochrome-labeled inhibitor of caspase-1 (FLICA) detection system. DAPI uptake and IL-1β release were monitored by flow cytometry. IL-1β enzyme-linked immunoassays (ELISAs) were performed according to Invitrogen Thermo Fisher Scientific (#BMS6002).

Differentiation between brain resident microglia and brain infiltrating macrophages was performed by FACS, where infiltrating cells were labeled CD45+CD11b+Ly6Chigh and microglia were labeled CD45intCD11b+ [36].

For functional analysis, brain cells from icv injected brain cells were stimulated with 0.5 mM ATP in RPMI containing DAPI at 37 °C for 5 min. Cells were washed and analyzed by flow cytometry.

Immunostaining

Mice were deeply anesthetized, and brains were fixed with 4% paraformaldehyde (PFA) by transcardial perfusion. After fixation in 4% PFA overnight, 50 µm thick sections were prepared using a vibratome. Immunostaining was performed at 4 °C on free-floating sections using an anti-Iba1 antibody to detect microglia (Fujifilm Wako Pure Chemical Corporation) and an anti-neuronal nuclear protein (NeuN) antibody to detect neurons (Thermo Fisher Scientific). DAPI (Thermo Fisher Scientific) was used to counterstain nuclei. Images were obtained by confocal laser scanning microscopy (LSM 880, Zeiss, Oberkochen, Germany).

Results

ATP is released rapidly after ischemic stroke

We analyzed ATP release after tMCAO by using ATP-sensing pmeLUC transgenic mice. These mice ubiquitously express firefly-derived luciferase on the outer layer of the plasma membrane [29, 37], which is activated by extracellular ATP. The pmeLUC mice can be used to detect changes in the extracellular ATP concentration in the micromolar range in a strictly ATP-selective fashion since the luciferase used is insensitive to all other nucleotides [37].

Immediately after tMCAO, a base image was taken (Fig. 1). At 90 min after artery occlusion, eATP release/luminescence increased in the ischemic hemisphere. After 24 h, we could still detect a strong signal in the ischemic hemisphere. Rough estimations of the in vivo eATP concentration were performed by an in vitro concentration gradient (Additional file 1: Fig. S4).

Fig. 1
figure 1

ATP was released after stroke. Transgenic ATP sensor mice (pmeLuc-mice) show eATP in the brain. A After tMCAO, ATP is rapidly released in the ischemic hemisphere starting after 30 min and is still prominent after 24 h compared to that in the contralateral hemisphere. B Sham-treated mice do not show substantial ATP level differences between the two hemispheres. Three mice for each group underwent surgery with similar results. Representative pictures are provided

Full size image

P2X7 overexpression exacerbates stroke volume

Immunostaining of P2X7-enhanced green fluorescent protein (EGFP) transgenic mice revealed that P2X7 is expressed mainly on ionized calcium-binding adapter molecule 1 (IbA1)-positive cells (Fig. 2A, negative controls in Additional file 1: Fig. S5). Merged staining of IbA1 and GFP showed, for the most part, a congruent symmetry, where neurons stained with NeuN did not show any GFP expression.

Fig. 2
figure 2

P2X7 was mainly expressed on microglia, and P2X7-overexpressing transgenic mice had more strokes. Immunostaining of 50 μm free-floating sections of P2X7-EGFP (A, n = 2) transgenic mice illustrated that P2X7 is highly expressed on IbA1-positive (red) cells compared to NeuN-positive (purple) neurons. DAPI (blue) was used to stain the nucleus. For the negative control, see Additional file 1: Fig. S5. B One day after tMCAO surgery, including an occlusion time of 40 min, the P2X7-overexpressing mice had a significantly higher infarct volume and a significantly higher % loss of parenchyma in the ischemic hemisphere. Statistical significance was analyzed by Student’s t test. **p < 0.001. Data are presented as the median ± range of 9 P2X7-overexpressing mice and 10 wild-type littermate controls. Representative TTC staining and representative overlays of stroke volume at day 1 following tMCAO treatment

Full size image

Additionally, we used the expression data from the Allen Brain Atlas for mice [18] and humans [19] to determine cellular P2X7 expression in the brain (Table 1).

Table 1 Expression of P2X receptor genes in brain resident cells in humans and mice
Full size table

To evaluate the relevance of P2X7 for ischemic stroke, we used P2X7-overexpressing mice [28]. Littermate mice (n = 10) and P2X7-overexpressing mice (n = 9) were subjected to tMCAO, and the stroke size was determined by TTC staining. After 40 min of occlusion, we found that stroke sizes in P2X7-overexpressing mice was significantly larger in comparison to wt controls 24 h after tMCAO. The P2X7-overexpressing mice had a mean ischemic volume of 52.50 mm3 ± 8.52 mm3 compared to the littermates with a mean ischemic volume of 36.66 mm3 ± 13.64 mm3(Fig. 2B). Additionally, the percentage of the ischemic hemisphere differed significantly between the two cohorts, with 49.36% ± 8.76% in the P2X7-overexpressing cohort and 34.15% ± 13.56% in the control group (Fig. 2B).

P2X7-specific nbs inhibit the P2X7 receptor on microglia in vitro

To verify that P2X7-specific nbs can inhibit the P2X7 receptor in microglia, we tested them in ATP-stimulated primary microglia in vitro. The P2X7-specific nbs (1 μg/ml) decreased the ATP-evoked calcium influx compared to the isotype control nbs (Fig. 3A). In addition, the P2X7-specific nbs dampened the ATP-evoked pore formation monitored by DAPI uptake (Fig. 3B). Caspase-1 activation, measured by the FAM-FLICA detection system, was reduced significantly in the presence of the P2X7-blocking nbs (Fig. 3C; mean fluorescence intensity [MFI]: 2617 vs. 674; ***p < 0.001; n = 3). LPS/ATP-evoked IL-1β release was significantly reduced after preincubation with the P2X7-specific nbs (Fig. 3D; ***p < 0.001; n = 3). Further investigation showed that low doses of nbs were sufficient to suppress IL-1β release (Fig. 3E).

Fig. 3
figure 3

P2X7-specific nbs influenced the P2X7 pathway in vitro. Primary microglia preincubated with P2X7-specific nbs showed a substantially lower calcium influx (monitored by Fluo4 [A]) and DAPI uptake (B) than those of the isotype control group after ATP (1.5 mM) challenge. As a positive control, ionomycin facilitated calcium influx across the plasma membrane. C In the absence of P2X7-specific nbs, stimulated microglia showed significantly higher caspase 1 activation (measured by the appearance of FAM-FLICA; n = 3) than ATP-activated microglia in the presence of these nbs. D Blockade of P2X7 by specific nbs dampened IL-1β release in cultured microglia after ATP and LPS stimulation. Both types of P2X7-specific nbs used in this investigation significantly decreased IL-1β release (n = 3). The findings in D are specified in E, showing that IL-1β release can be reduced by using even low doses of nbs. Statistical significance was determined by Student’s t test. ***p < 0.0001

Full size image

Iv injection of P2X7-specific nbs does not affect stroke size

Next, we investigated the effect of the P2X7-specific nbs on stroke size in wild-type mice. We intravenously injected 100 μg of nb B prior to tMCAO. Stroke size was analyzed 24 h after surgery in two independent cohorts by histology or MRI. We did not find any significant reduction in stroke size compared to that of the isotype control nb group (MRI and TTC: p > 0.05). The isotype-treated wild-type mice showed ischemic lesions of 60.91% ± 12.23% in the ischemic hemisphere in the TTC cohort and 62.92% ± 1.68% in the MRI cohort. The nb-treated mice showed an almost identical ischemic lesions, with 59.41% ± 15.13% in the TTC cohort and 63.72% ± 3.73% in the MRI cohort (Fig. 4A).

Fig. 4
figure 4

Intravenously injected P2X7-blocking nbs did not cross the BBB and did not influence stroke size. C57BL6J mice intravenously received 100 μg of P2X7-specific nbs or isotype control nbs after tMCAO surgery. Twenty-four hours after stroke, lesion size was measured via MRI and TTC. Between both groups, the % of parenchymal loss in the ischemic hemisphere did not differ significantly (A; TTC: isotype n = 13 vs. P2X7-specific nb n = 7; MRI: isotype n = 8 vs. P2X7-specific nb n = 8). Statistical significance was determine by Student’s t test. B For determination of whether nbs cross the BBB, the brains of iv nb-treated mice were analyzed 24 h after treatment and stroke. After injection of 100 μg of nbs conjugated with AlexaFluor647, infiltrating macrophages (C; CD45+CD11b+Ly6Chigh) were covered with P2X7-specific nbs, whereas brain resident microglia (C; CD45+CD11intermedLy6Clow) did not show any P2X7-specific nb on their surface by flow cytometry. As a positive control, 0.5 μg of nb A was added ex vivo

Full size image

To detect whether the nbs successfully cross the blood–brain barrier (BBB), we intravenously injected fluorophore-labeled P2X7-specific nbs 1 h after tMCAO. After 24 h, we analyzed the MFI of P2X7-specific nbs bound to either brain resident microglia or brain infiltrating macrophages (see staining protocol in Additional file 1: Fig. S1). We found that 100 µg of intravenously injected nbs did not label brain resident microglia but could be detected on infiltrating macrophages (Fig. 4B), indicating an insufficient passage through the BBB of the nbs. This insufficient passage was further verified by a dose–response analysis of intravenously injected nbs (Additional file 1: Fig. S6), indicating that extremely high doses are needed for BBB crossing.

Icv injection of P2X7-specific nbs reduces stroke size

To circumvent the BBB, we performed direct icv injection of nbs into the brain and examined the effect of these P2X7-specific nbs on stroke size. Because of the minimal volume of 1–2 μl available for icv injections, we needed to concentrate the nbs. For this, we had to slightly modify nb B (see MM). After performing a dose–response analysis of icv injected nbs, we saw that 10 to 30 μg were already sufficient to cover the P2X7 receptor on all microglia and could be detected up to 21 days after injection (Additional file 1: Figs. S7, S8).

Following our dose response curve we injected 30 μg of this modified P2X7-specific nb B-mod (n = 8) or an isotype control nb (n = 9) intracerebroventricularly into wildtype mice. Twenty-four hours after tMCAO, we analyzed the stroke size and found that the P2X7-specific nbs resulted in significantly decreased stroke sizes (26.16 mm3 ± 10.29 mm3 compared to isotype 42.02 mm3 ± 8.49 mm3; ***p < 0.01; Fig. 5A). This effect was also reflected by the loss of viable tissue (22.78% ± 8.84% compared to isotype 38.00% ± 8.32%; ***p < 0.01; Fig. 5A). Flow cytometry of brain resident microglia of these mice showed a strong signal of the P2X7-specific nbs (Fig. 5B). This signal could not be further increased by ex vivo addition of the P2X7-specific nbs. Functional P2X7 activation after icv injection of nbs was tested by analysis of ATP-induced DAPI uptake (Fig. 5C). Then, 160 min after icv injection of the P2X7-specific nbs, microglia were isolated from the brain and activated by ATP. Microglia exposed to the P2X7-specific nbs in vivo showed substantially lower DAPI uptake. After in vivo icv injection of 30 μg and administration of 0.5 mM ATP 61.9% of the microglia were protected from P2X7 activation and accordingly from DAPI-uptake. As a positive control DAPI-uptake in the absence of nbs and the presence of 0.5 mM ATP was 89.5%. The negative control without any nbs or ATP resulted in a DAPI-uptake of 1.4% (Table 2).

Fig. 5
figure 5

Icv injection of P2X7 nbs significantly reduced stroke size. P2X7-blocking nbs (30 μg) were injected intracerebroventricularly directly before tMCAO surgery of C57BL6J mice. Twenty-four hours after tMCAO, the mice were sacrificed. The mice treated with P2X7-blocking nbs showed significantly smaller ischemic volumes and a significantly smaller % of parenchyma loss in the ischemic hemisphere than the mice treated with a control isotype nbs. A Flow cytometry of brain resident microglia showed full coverage by P2X7-specific nbs compared to the controls (gating strategy Additional file 1: Fig. S2). Statistical significance was determined by Student’s t test. ***p < 0.001 Data are presented as the median ± SD of 8 P2X7-specific nb-injected mice and 9 isotype control-injected mice. B Representative TTC staining and representative overlays of stroke volume at 24 h following tMCAO. C 160 min after icv injection or ex vivo administration of 30 μg of P2X7-specific nbs, isolated microglia showed substantially lower DAPI uptake. Microglia in the absence of nbs and ATP did not show any DAPI uptake

Full size image
Table 2 DAPI-uptake of microglia after icv injection of P2X7 specific nb-B mod
Full size table

Discussion

Here, we show that eATP is present early after cerebral ischemia and that blocking the ATP receptor P2X7 with specific nbs diminishes the tissue damage caused by ischemia. However, the nbs need to be injected intracerebroventricularly to bypass the BBB and reach the P2X7 receptor on brain resident cells.

Mounting evidence indicates that stroke triggers a sterile inflammatory response. The injured tissue releases a myriad of molecules that can activate the surrounding or infiltrating immune cells. Potent activators of local immune responses are danger-associated molecular patterns (DAMPs). Some of these endogenous danger signals can induce activation of the inflammasome and the secretion of proinflammatory cytokines by innate immune cells [4, 38]. Using transgenic mice that express luciferase on the outer layer of the cell membrane, we showed that similar to traumatic brain injury [39], eATP is released very early during ischemic tissue damage. In addition, the signal is sustained over 24 h, clearly indicating an ongoing release of eATP in the ischemic tissue. Therefore, eATP and its cognate receptors likely play an important role in the initiation of the inflammatory reaction following stroke. eATP activates purinergic receptors. While the microglial P2Y12 receptor is important for microglial neuron interactions, the proinflammatory response by microglia is likely triggered by P2X7, which is highly expressed by microglia [40,41,42].

P2X7 is expressed in the brain mainly on glial cells. Expression data from the Allen Brain Atlas for mice [18] and humans [19] show that the P2X7 receptor is highly expressed by microglia in humans and rodents (Table 1). In contrast, astrocytes show low levels of P2X7 RNA. Species-specific differences in P2X7 expression can be found for oligodendrocytes, where P2X7 is highly expressed by human oligodendrocytes but not by murine oligodendrocytes. Therefore, it is likely that in rodents, the main effect of blocking P2X7 is mediated through microglial cells.

After ischemic stroke, the expression of P2X7 is increased on microglia [43, 44] and can induce cell death in ischemic microglia [15]. This increase in P2X7 expression is not found in astrocytes after ischemic stroke [17]. We and others have shown that experimental stroke in P2X7-/- mice results in smaller infarcts and that blockade of P2X7 with BBG reduces cerebral ischemic damage [20, 45]. In addition, the inhibition of the NLRP3 inflammasome decreased the amount of damage after cerebral ischemia, but there was no additional benefit if P2X7 was also blocked [20]. These data are still controversial [12]. Yanagisawa and colleagues observed an exacerbation of ischemic brain damage when P2X7 was blocked. Similar findings were also reported by Kang et al. [46], who observed an effect on ciliary neurotrophic factor (CNTF) production but no effect on lesion size. One explanation for these discrepancies is the use of BBG. Small molecule inhibitors are often semispecific and toxic. In particular, BBG is not specific for P2X7 [47] and is known to have dose-dependent off-target effects. Therefore, we used nbs that we had recently developed and are currently in the process of being patented (see MM; WO/2013/178783) [10]. We not only generated several different families of murine P2X7-specific nbs but also different human P2X7-specific nbs. Nbs, recombinant single domain antibodies derived from camelid heavy chain antibodies, are a promising new technology platform. The first nb-based reagents developed by Ablynx-Sanofi have entered clinical trials and have achieved FDA approval (targeting TNF-α, von Willebrand factor, receptor activator of nuclear factor κB [RANK]-ligand, and IL-6 receptor [48, 49]).

The BBB is a major obstacle for the treatment of brain disease with biologicals. Under healthy conditions, the BBB is only permeable for lipophilic molecules of up to 400 kDa [50]. In addition, the delivery of conventional antibodies to the brain is further hampered by Fc receptor-mediated efflux to the blood [51]. Therefore, nbs lacking an Fc part may reach targets behind the BBB. However, under nonpathological conditions, monovalent nbs do not attain sufficient concentrations for in vivo brain imaging [52] or therapeutic purposes [53]. In stroke, biphasic BBB breakdown is caused by activated matrix metalloproteinase (MMP)-2, MMP-3 and MMP-9 [54, 55]. The breakdown of the BBB is initially reversible but is further increased with the release of MMP-3 and MMP-9 [56]. These findings suggest that antibodies or nbs would have easier access to the brain in ischemic stroke. However, as we can show here, only a minor portion of the intravenously injected nbs reached the brain. While macrophages from the bloodstream were quickly covered with intravenously injected nbs, when they reached the brain, microglia did not carry any nbs, and their function was unimpaired (Fig. 4). These findings are similar to observations in antibodies crossing the BBB, where a direct shuttle system such as the transferrin receptor is usually needed to enter the brain [57]. Since this problem prevents noninvasive iv administration of the nbs, it is necessary to find strategies to facilitate the transport of nbs across the BBB. For this study, we chose to directly inject our nbs into the ventricular system of the brain, which is difficult in the mouse system because of the small volume that can be injected. We were able to modify our nbs so they could be highly concentrated without aggregating (Additional file 1: Fig. S1). In humans, nb delivery would be less of a problem since it could be accomplished by lumbar puncture and injection into the cerebral spinal fluid (CSF). Direct injection in the CSF of therapeutics is already used for other neurological diseases, such as neuronal ceroid lipofuscinosis [58]. Other promising possibilities for nb delivery to the CNS include the fusion of nbs to ligands of brain-endothelial receptors such as ApoE-LDL-receptor or to nbs directed against cell transcytosis receptors on cerebral endothelial cells [59,60,61].

In stroke, microglia are the first immune cells to respond, while macrophages enter the brain at later stages [32]. Therefore, it is not surprising that there was no difference in ischemic lesion size after iv nb injection, where the nbs could not pass the BBB. In contrast, after an icv injection of P2X7-specific nbs, we could reach up to 95% of the microglia. This level of P2X7R blockade was sufficient to inhibit microglial activation and improve the outcome. Our study shows that inhibition of signaling by eATP is only effective if it is done early and reaches locally expressed P2X7 in the brain.

Limitations

Our study was a proof-of-concept study, which was not designed to simulate the clinical setting. Further studies are needed to determine whether P2X7-specific nbs improve outcomes after stroke, how they influence long-term outcomes, and if they are similarly effective in female, comorbid and old mice. Our results will have to be reproduced in other laboratories and other model systems before translation.

Conclusion

Here, we demonstrate the importance of locally produced eATP for the damage in ischemic stroke and the potential of intracerebroventricularly injected P2X7 nbs to reduce this damage.

Availability of data and materials

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Change history

  • 15 January 2023

    Missing Open Access funding information has been added in the Funding Note.

Abbreviations

nbs:

Nanobodies

wt:

Wild-type

tg:

Transgenic

tMCAO:

Temporary middle cerebral artery occlusion

iv:

Intravenous

ip:

Intraperitoneal

icv:

Intracerebroventricular

DAPI:

4,6-Diamidino-2-phenylindole

IL:

Interleukin

(e)ATP:

(Extracellular) adenosine triphosphate

FACS:

Fluorescence-activated cell sorting

h:

Hours

NAD:

Nicotinamide adenine dinucleotide

HSP:

Heat shock protein

HMGB1:

High-mobility group box 1 protein

NFκB:

Nuclear factor kappa-light-chain-enhancer of activated B cells

NLRP3:

Nod-like receptor protein 3

TLR:

Toll-like receptors

TNF:

Tumor necrosis factor

CNS:

Central nervous system

BBG:

Brilliant blue G

sdAbs:

Single domain antibodies

CDR3:

Complementarity determining region 3

(E)GFP:

Enhanced green fluorescent protein

CH:

Constant domain heavy chain

Ig:

Immunoglobulin

SDS-PAGE:

Sodium dodecyl sulfate–polyacrylamide gel electrophoresis

CCA:

Common carotid artery

ECA:

External carotid artery

MRI:

Magnetic resonance imaging

TTC:

Triphenyl tetrazolium chloride

PBS:

Phosphate-buffered saline

CD:

Cluster of differentiation

BV:

Brilliant violet

FLICA:

Fluorochrome-labeled inhibitors of caspases

ELISA:

Enzyme-linked immunoassay

PFA:

Paraformaldehyde

IbA1:

Ionized calcium-binding adapter molecule 1

NeuN:

Neuronal nuclear protein

BBB:

Blood–brain barrier

MFI:

Mean fluorescence intensity

DAMPs:

Damage-associated molecular patterns

RNA:

Ribonucleic acid

MFCNTF:

Ciliary neuronotrophic factor

RANK:

Receptor activator of nuclear factor k

MMP:

Matrix metalloproteinases

CSF:

Cerebral spinal fluid

ApoB:

Apolipoprotein B

LDL:

Low density lipoprotein receptor

References

  1. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 1999;22:391–7.

    Article  CAS  PubMed  Google Scholar 

  2. Huang J, Upadhyay UM, Tamargo RJ. Inflammation in stroke and focal cerebral ischemia. Surg Neurol. 2006;66:232–45.

    Article  PubMed  Google Scholar 

  3. Jones KA, Maltby S, Plank MW, Kluge M, Nilsson M, Foster PS, Walker FR. Peripheral immune cells infiltrate into sites of secondary neurodegeneration after ischemic stroke. Brain Behav Immun. 2018;67:299–307.

    Article  CAS  PubMed  Google Scholar 

  4. Di Virgilio F. Liaisons dangereuses: P2X(7) and the inflammasome. Trends Pharmacol Sci. 2007;28:465–72.

    Article  PubMed  Google Scholar 

  5. Broz P, Dixit VM. Inflammasomes: mechanism of assembly, regulation and signalling. Nat Rev Immunol. 2016;16:407–20.

    Article  CAS  PubMed  Google Scholar 

  6. Gelderblom M, Sobey CG, Kleinschnitz C, Magnus T. Danger signals in stroke. Ageing Res Rev. 2015;24:77–82.

    Article  PubMed  Google Scholar 

  7. Rissiek B, Haag F, Boyer O, Koch-Nolte F, Adriouch S. P2X7 on Mouse T cells: one channel many functions. Front Immunol. 2015;6:204.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Hattori M, Gouaux E. Molecular mechanism of ATP binding and ion channel activation in P2X receptors. Nature. 2012;485:207–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Kasuya G, Yamaura T, Ma XB, Nakamura R, Takemoto M, Nagumo H, Tanaka E, Dohmae N, Nakane T, Yu Y, et al. Structural insights into the competitive inhibition of the ATP-gated P2X receptor channel. Nat Commun. 2017;8:876.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Danquah W, Meyer-Schwesinger C, Rissiek B, Pinto C, Serracant-Prat A, Amadi M, Iacenda D, Knop JH, Hammel A, Bergmann P, et al. Nanobodies that block gating of the P2X7 ion channel ameliorate inflammation. Sci Transl Med. 2016;8:366–462.

    Article  Google Scholar 

  11. Munoz-Planillo R, Kuffa P, Martinez-Colon G, Smith BL, Rajendiran TM, Nunez G. K(+) efflux is the common trigger of NLRP3 inflammasome activation by bacterial toxins and particulate matter. Immunity. 2013;38:1142–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Yanagisawa D, Kitamura Y, Takata K, Hide I, Nakata Y, Taniguchi T. Possible involvement of P2X7 receptor activation in microglial neuroprotection against focal cerebral ischemia in rats. Biol Pharm Bull. 2008;31:1121–30.

    Article  CAS  PubMed  Google Scholar 

  13. Janks L, Sharma CVR, Egan TM. A central role for P2X7 receptors in human microglia. J Neuroinflam. 2018;15:325.

    Article  CAS  Google Scholar 

  14. He Y, Taylor N, Fourgeaud L, Bhattacharya A. The role of microglial P2X7: modulation of cell death and cytokine release. J Neuroinflam. 2017;14:135.

    Article  Google Scholar 

  15. Eyo UB, Miner SA, Ahlers KE, Wu LJ, Dailey ME. P2X7 receptor activation regulates microglial cell death during oxygen-glucose deprivation. Neuropharmacology. 2013;73:311–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Hirayama Y, Anzai N, Koizumi S. Mechanisms underlying sensitization of P2X7 receptors in astrocytes for induction of ischemic tolerance. Glia. 2021;69:2100–10.

    Article  CAS  PubMed  Google Scholar 

  17. Zamanian JL, Xu L, Foo LC, Nouri N, Zhou L, Giffard RG, Barres BA. Genomic analysis of reactive astrogliosis. J Neurosci. 2012;32:6391–410.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Lein ES, Hawrylycz MJ, Ao N, Ayres M, Bensinger A, Bernard A, Boe AF, Boguski MS, Brockway KS, Byrnes EJ, et al. Genome-wide atlas of gene expression in the adult mouse brain. Nature. 2007;445:168–76.

    Article  CAS  PubMed  Google Scholar 

  19. Hodge RD, Bakken TE, Miller JA, Smith KA, Barkan ER, Graybuck LT, Close JL, Long B, Johansen N, Penn O, et al. Conserved cell types with divergent features in human versus mouse cortex. Nature. 2019;573:61–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Cisneros-Mejorado A, Gottlieb M, Cavaliere F, Magnus T, Koch-Nolte F, Scemes E, Perez-Samartin A, Matute C. Blockade of P2X7 receptors or pannexin-1 channels similarly attenuates postischemic damage. J Cereb Blood Flow Metab. 2015;35:843–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Menzel S, Schwarz N, Haag F, Koch-Nolte F. Nanobody-based biologics for modulating purinergic signaling in inflammation and immunity. Front Pharmacol. 2018;9:266.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Hu Y, Liu C, Muyldermans S. Nanobody-based delivery systems for diagnosis and targeted tumor therapy. Front Immunol. 2017;8:1442.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Rissiek B, Koch-Nolte F, Magnus T. Nanobodies as modulators of inflammation: potential applications for acute brain injury. Front Cell Neurosci. 2014;8:344.

    Article  PubMed  PubMed Central  Google Scholar 

  24. De Genst E, Saerens D, Muyldermans S, Conrath K. Antibody repertoire development in camelids. Dev Comp Immunol. 2006;30:187–98.

    Article  PubMed  Google Scholar 

  25. Koch-Nolte F, Reyelt J, Schossow B, Schwarz N, Scheuplein F, Rothenburg S, Haag F, Alzogaray V, Cauerhff A, Goldbaum FA. Single domain antibodies from llama effectively and specifically block T cell ecto-ADP-ribosyltransferase ART2.2 in vivo. FASEB J. 2007;21:3490–8.

    Article  CAS  PubMed  Google Scholar 

  26. Ingram JR, Schmidt FI, Ploegh HL. Exploiting Nanobodies’ Singular Traits. Annu Rev Immunol. 2018;36:695–715.

    Article  CAS  PubMed  Google Scholar 

  27. Wesolowski J, Alzogaray V, Reyelt J, Unger M, Juarez K, Urrutia M, Cauerhff A, Danquah W, Rissiek B, Scheuplein F, et al. Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. Med Microbiol Immunol. 2009;198:157–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Kaczmarek-Hajek K, Zhang J, Kopp R, Grosche A, Rissiek B, Saul A, Bruzzone S, Engel T, Jooss T, Krautloher A, et al. Re-evaluation of neuronal P2X7 expression using novel mouse models and a P2X7-specific nanobody. Elife. 2018;7:67.

    Article  Google Scholar 

  29. Csoka B, Nemeth ZH, Szabo I, Davies DL, Varga ZV, Paloczi J, Falzoni S, Di Virgilio F, Muramatsu R, Yamashita T, et al. Macrophage P2X4 receptors augment bacterial killing and protect against sepsis. JCI Insight. 2018;3:89.

    Article  Google Scholar 

  30. Jager V, Bussow K, Wagner A, Weber S, Hust M, Frenzel A, Schirrmann T. High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells. BMC Biotechnol. 2013;13:52.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Tijink BM, Laeremans T, Budde M, Stigter-van Walsum M, Dreier T, de Haard HJ, Leemans CR, van Dongen GA. Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology. Mol Cancer Ther. 2008;7:2288–97.

    Article  CAS  PubMed  Google Scholar 

  32. Gelderblom M, Leypoldt F, Steinbach K, Behrens D, Choe CU, Siler DA, Arumugam TV, Orthey E, Gerloff C, Tolosa E, Magnus T. Temporal and spatial dynamics of cerebral immune cell accumulation in stroke. Stroke. 2009;40:1849–57.

    Article  PubMed  Google Scholar 

  33. Gelderblom M, Weymar A, Bernreuther C, Velden J, Arunachalam P, Steinbach K, Orthey E, Arumugam TV, Leypoldt F, Simova O, et al. Neutralization of the IL-17 axis diminishes neutrophil invasion and protects from ischemic stroke. Blood. 2012;120:3793–802.

    Article  CAS  PubMed  Google Scholar 

  34. Lourbopoulos A, Mamrak U, Roth S, Balbi M, Shrouder J, Liesz A, Hellal F, Plesnila N. Inadequate food and water intake determine mortality following stroke in mice. J Cereb Blood Flow Metab. 2017;37:2084–97.

    Article  PubMed  Google Scholar 

  35. Gerriets T, Stolz E, Walberer M, Muller C, Kluge A, Bachmann A, Fisher M, Kaps M, Bachmann G. Noninvasive quantification of brain edema and the space-occupying effect in rat stroke models using magnetic resonance imaging. Stroke. 2004;35:566–71.

    Article  CAS  PubMed  Google Scholar 

  36. Grabert K, Michoel T, Karavolos MH, Clohisey S, Baillie JK, Stevens MP, Freeman TC, Summers KM, McColl BW. Microglial brain region-dependent diversity and selective regional sensitivities to aging. Nat Neurosci. 2016;19:504–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Pellegatti P, Falzoni S, Pinton P, Rizzuto R, Di Virgilio F. A novel recombinant plasma membrane-targeted luciferase reveals a new pathway for ATP secretion. Mol Biol Cell. 2005;16:3659–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Junger WG. Immune cell regulation by autocrine purinergic signalling. Nat Rev Immunol. 2011;11:201–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Faroqi AH, Lim MJ, Kee EC, Lee JH, Burgess JD, Chen R, Di Virgilio F, Delenclos M, McLean PJ. In vivo detection of extracellular adenosine triphosphate in a mouse model of traumatic brain injury. J Neurotrauma. 2021;38:655–64.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Cserep C, Posfai B, Lenart N, Fekete R, Laszlo ZI, Lele Z, Orsolits B, Molnar G, Heindl S, Schwarcz AD, et al. Microglia monitor and protect neuronal function through specialized somatic purinergic junctions. Science. 2020;367:528–37.

    Article  CAS  PubMed  Google Scholar 

  41. Di Virgilio F, Sarti AC, Grassi F. Modulation of innate and adaptive immunity by P2X ion channels. Curr Opin Immunol. 2018;52:51–9.

    Article  PubMed  Google Scholar 

  42. Linden J, Koch-Nolte F, Dahl G. Purine release, metabolism, and signaling in the inflammatory response. Annu Rev Immunol. 2019;37:325–47.

    Article  CAS  PubMed  Google Scholar 

  43. Skaper SD. Ion channels on microglia: therapeutic targets for neuroprotection. CNS Neurol Disord Drug Targets. 2011;10:44–56.

    Article  CAS  PubMed  Google Scholar 

  44. Franke H, Gunther A, Grosche J, Schmidt R, Rossner S, Reinhardt R, Faber-Zuschratter H, Schneider D, Illes P. P2X7 receptor expression after ischemia in the cerebral cortex of rats. J Neuropathol Exp Neurol. 2004;63:686–99.

    Article  CAS  PubMed  Google Scholar 

  45. Arbeloa J, Perez-Samartin A, Gottlieb M, Matute C. P2X7 receptor blockade prevents ATP excitotoxicity in neurons and reduces brain damage after ischemia. Neurobiol Dis. 2012;45:954–61.

    Article  CAS  PubMed  Google Scholar 

  46. Kang SS, Keasey MP, Hagg T. P2X7 receptor inhibition increases CNTF in the subventricular zone, but not neurogenesis or neuroprotection after stroke in adult mice. Transl Stroke Res. 2013;4:533–45.

    Article  CAS  PubMed  Google Scholar 

  47. Jiang L-H, Mackenzie AB, North RA, Surprenant A. Brilliant Blue G Selectively Blocks ATP-Gated Rat P2X7Receptors. Mol Pharmacol. 2000;58:82–8.

    Article  CAS  PubMed  Google Scholar 

  48. Ulrichts H, Silence K, Schoolmeester A, de Jaegere P, Rossenu S, Roodt J, Priem S, Lauwereys M, Casteels P, Van Bockstaele F, et al. Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs. Blood. 2011;118:757–65.

    Article  CAS  PubMed  Google Scholar 

  49. Scully M, Cataland SR, Peyvandi F, Coppo P, Knobl P, Kremer Hovinga JA, Metjian A, de la Rubia J, Pavenski K, Callewaert F, et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2019;380:335–46.

    Article  CAS  PubMed  Google Scholar 

  50. Pardridge WM. Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab. 2012;32:1959–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Cooper PR, Ciambrone GJ, Kliwinski CM, Maze E, Johnson L, Li Q, Feng Y, Hornby PJ. Efflux of monoclonal antibodies from rat brain by neonatal Fc receptor FcRn. Brain Res. 2013;1534:13–21.

    Article  CAS  PubMed  Google Scholar 

  52. Nabuurs RJ, Rutgers KS, Welling MM, Metaxas A, de Backer ME, Rotman M, Bacskai BJ, van Buchem MA, van der Maarel SM, van der Weerd L. In vivo detection of amyloid-beta deposits using heavy chain antibody fragments in a transgenic mouse model for Alzheimer’s disease. PLoS ONE. 2012;7: e38284.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Caljon G, Caveliers V, Lahoutte T, Stijlemans B, Ghassabeh GH, Van Den Abbeele J, Smolders I, De Baetselier P, Michotte Y, Muyldermans S, et al. Using microdialysis to analyse the passage of monovalent nanobodies through the blood-brain barrier. Br J Pharmacol. 2012;165:2341–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Ludewig P, Sedlacik J, Gelderblom M, Bernreuther C, Korkusuz Y, Wagener C, Gerloff C, Fiehler J, Magnus T, Horst AK. Carcinoembryonic antigen-related cell adhesion molecule 1 inhibits MMP-9-mediated blood-brain-barrier breakdown in a mouse model for ischemic stroke. Circ Res. 2013;113:1013–22.

    Article  CAS  PubMed  Google Scholar 

  55. Yang Y, Rosenberg GA. Blood-brain barrier breakdown in acute and chronic cerebrovascular disease. Stroke. 2011;42:3323–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Rosell A, Cuadrado E, Ortega-Aznar A, Hernandez-Guillamon M, Lo EH, Montaner J. MMP-9-positive neutrophil infiltration is associated to blood-brain barrier breakdown and basal lamina type IV collagen degradation during hemorrhagic transformation after human ischemic stroke. Stroke. 2008;39:1121–6.

    Article  CAS  PubMed  Google Scholar 

  57. Lee HJ, Engelhardt B, Lesley J, Bickel U, Pardridge WM. Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse. J Pharmacol Exp Ther. 2000;292:1048–52.

    CAS  PubMed  Google Scholar 

  58. Worgall S, Sondhi D, Hackett NR, Kosofsky B, Kekatpure MV, Neyzi N, Dyke JP, Ballon D, Heier L, Greenwald BM, et al. Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Hum Gene Ther. 2008;19:463–74.

    Article  CAS  PubMed  Google Scholar 

  59. Sarkar G, Curran GL, Mahlum E, Decklever T, Wengenack TM, Blahnik A, Hoesley B, Lowe VJ, Poduslo JF, Jenkins RB. A carrier for non-covalent delivery of functional beta-galactosidase and antibodies against amyloid plaques and IgM to the brain. PLoS ONE. 2011;6: e28881.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Muruganandam A, Tanha J, Narang S, Stanimirovic D. Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood-brain barrier endothelium. FASEB J. 2002;16:240–2.

    Article  CAS  PubMed  Google Scholar 

  61. Abulrob A, Sprong H. The blood-brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells. J Neurochem. 2005;95:1201–14.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Lennart Pöls and Oliver Schnapauff for excellent technical assistance. We also thank the departments of Radiology and Neuroradiology of the UKE for assistance with the MRI measurements.

Funding

Open Access funding enabled and organized by Projekt DEAL. This research was supported by the DFG Research Unit FOR 2879 Immunostroke (projects A1 [4248778651] to TM, A3 [428663564] to TM and AL), SFB 1328 (project A13 to TM and ET, A15 to ET), the ‘Hermann und Lilly Schilling Stiftung’ to TM and Else-Kröner Stiftung to MW and JS, and by the Italian Association for Cancer Research (AIRC) grant no. IG 22883 to FDV.

Author information

Author notes

  1. Nikolaus Plesnilla, Friedrich Koch-Nolte and Tim Magnus equally contributing last authors

Authors and Affiliations

  1. Department of Neurology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany

    Maximilian Wilmes, Carolina Pinto Espinoza, Peter Ludewig, Joschi Stabernack, Mathias Gelderblom, Christian Gerloff, Björn Rissiek & Tim Magnus

  2. Institute of Immunology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany

    Carolina Pinto Espinoza, Eva Tolosa & Friedrich Koch-Nolte

  3. Institute for Stroke and Dementia Research, University Medical Center, 813777, Munich, Germany

    Arthur Liesz & Nikolaus Plesnilla

  4. SyNergy Cluster for Systems Neurology, 81377, Munich, Germany

    Annette Nicke

  5. Walther Straub Institute of Pharmacology and Toxicology, Ludwig-Maximilians-Universität München, Munich, Germany

    Arthur Liesz

  6. Department of Medical Sciences, University of Ferrara, Ferrara, Italy

    Simonetta Falzoni & Francesco Di Virgilio

Authors
  1. Maximilian Wilmes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carolina Pinto Espinoza
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Ludewig
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Joschi Stabernack
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Arthur Liesz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Annette Nicke
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mathias Gelderblom
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Christian Gerloff
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Simonetta Falzoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Eva Tolosa
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Francesco Di Virgilio
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Björn Rissiek
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Nikolaus Plesnilla
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Friedrich Koch-Nolte
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Tim Magnus
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

TM, FN, BR, MG, CP and MW designed the study. MW, CP, PL, JS, AL, AN, MG, SF, FDV and BR carried out various experiments and acquired and analyzed the data. MW, TM, MG, CG, ET, FDV, BR, AL, FN wrote the manuscript and edited the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Tim Magnus.

Ethics declarations

Ethics approval and consent to participate

All animal experiments were approved by local animal care committees (Behörde für Justiz und Verbraucherschutz der Freien und Hansestadt Hamburg; Lebensmittelsicherheit und Veterinärwesen, Hamburg Germany, permission number: 006/18). This was a purely animal study with no involvement of patients.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: Figure S1.

The nbs used and their staining procedure. For this study, different nb constructs were used. The 13A7 nb (P2X7-specific nb; see patent WO/2013/178783; [10]) was fused to the hinge, CH2, and CH3 domains of mouse IgG2c, resulting in a heavy chain format (nb A), whereas 1c81 (P2X7-specific nb; see patent WO/2013/178783 [10]) was dimerized and fused to the albumin-specific nb Alb8 (nb B). To prevent aggregation at high concentrations, we modified nb B (nb B-mod). For recognition of these nbs in FACS, we used the following staining protocols: After binding of nb A to P2X7, cells were stained with a biotinylated anti-mouse IgG2c-fused antibody followed by streptavidin BV421 conjugation. After binding of nb B-mod, cells were stained with an anti-Alb8-nb fused to the mouse IgG1 heavy chain backbone, followed by an anti-mouse IgG1 antibody conjugated with BV421. Figure S2. Schematic representation of icv surgery. The cranial burr hole was drilled 1.1 mm lateral and 0.5 mm posterior to bregma. Nbs were injected 2.3 mm deep directly into the left ventricular system. As a proof-of-concept, 2 μl of 5% Evans blue was injected into the ventricular system. Two hours after injection, Evans blue was distributed equally in the whole ventricular system. Figure S3. Gating strategy for brain resident microglia. Flow cytometry of brain cells. Three minutes before euthanasia, a CD45-fluorochrome-conjugated antibody was injected intravenously to separate intravascular from intraparenchymal cells. Brain resident microglia were identified as CD45intermed CD11bhigh cells, which were not labeled by the intravenously injected CD45-fluorochrome conjugated antibody. Figure S4. In vitro calibration of brain homogenates from pmeLUC mice. The panel shows the in vitro calibration of brain homogenates from pmeLUC mice, showing the luminescence response to the addition of exogenous ATP and the obliteration of luminescence in the presence of the ATP-hydrolyzing enzyme apyrase. With all the caveats due to the in vitro setting, this calibration suggests that the eATP concentration in the stroked brain may reach hundreds of micromoles/L. Figure S5. Negative control. In GFP-negative littermates, no P2X7 signal was found. Figure S6. High doses of P2X7-blocking nbs are necessary to cross the BBB efficiently. C57BL6J mice received different amounts of nb A intravenously. Four hours after iv injection mice were sacrificed and nbs bound to microglia were labeled by FACS (See MM). Full coverage of P2X7 was reached with 3200 μg, where 1000 μg and lower concentrations achieved less than 60% occupancy of microglial P2X7. These FACS data are representative images of two independent cohorts of 5 mice each. Figure S7. Low amounts of icv injectedP2X7-blocking nb B-mod showed high P2X7 occupancy on microglia. C57BL6J mice received different amounts of P2X7-specific nbs intracerebroventricularly. 18 h after icv injection mice were sacrificed and nbs bound to microglia were labeled by FACS (See MM). Low amounts of P2X7 blocking nb B-mod were needed to show almost full occupancy of microglial P2X7 receptor. These FACS data are representative images of two independent cohorts of 5 mice each. Figure S8. Icv injection of P2X7-blocking nb B-mod resulted in a long time P2X7 occupancy on microglia. C57BL6J mice received 30 μg P2X7-specific nb-B mod intracerebroventricularly. Mice were sacrificed at different time points after icv injection and nbs bound to microglia were labeled by FACS (See MM). After 2.5 h microglial P2X7 showed nearly complete coverage by P2X7 nbs. This high occupancy started to decrease 14 days after the icv injection, but still nearly 40% of microglial P2X7 was occupied after 21 days post icv injection. These FACS data are representative images of two independent cohorts of 6 mice each.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wilmes, M., Pinto Espinoza, C., Ludewig, P. et al. Blocking P2X7 by intracerebroventricular injection of P2X7-specific nanobodies reduces stroke lesions. J Neuroinflammation 19, 256 (2022). https://doi.org/10.1186/s12974-022-02601-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12974-022-02601-z

Keywords

Journal of Neuroinflammation

ISSN: 1742-2094